Objective: To evaluate the clinical utility of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide as a treatment for patients with hormone-refractory prostate cancer. Methods: Fifty-seven patients with hormone-refractory prostate cancer were treated with an oral administration of dexamethasone (1.0 mg/day), uracil plus tegafur (400 mg/day) and cyclophosphamide (100 mg/day). The median patient age was 71 years. Sixteen patients had symptomatic bone metastasis, 31 had asymptomatic bone metastasis and 8 showed lymph node metastasis. Eight patients presented with only biochemical progression as evaluated by serum prostate-specific antigen levels. Results: Thirty-six (63%) of 57 patients demonstrated a 50% decline in serum prostatespecific antigen levels. The median time to prostate-specific antigen progression was 7.2 months. In patients with a prostate-specific antigen decline of 50%, the median time to progression was 13.3 months. With respect to pre-treatment markers, the duration of response to initial hormonal treatment was associated with the time to prostate-specific antigen progression. In 11 of 16 (69%) patients who complained of bone pain, the pain improved and became stable in 5 of those patients (31%). Most adverse events were mild and only three (5%) patients showed neutropenia of Grade 3 or higher. Conclusions: The combination of dexamethasone, uracil plus tegafur and cyclophosphamide is an effective and well tolerated regimen for hormone-refractory prostate cancer. To evaluate the survival benefits, further randomized studies are required.
INTRODUCTION
Male prostate cancer is the second leading cause of cancer in the USA (1) and is a growing problem worldwide. Most patients with advanced prostate cancer will respond to testicular androgen blockade, castration or use of a luteinizing hormone-releasing hormone (LHRH) analogue with or without antiandrogen. The median duration of response, however, is ,2 years after initial hormonal therapy for these patients (2, 3) . Once the disease becomes hormone-refractory prostate cancer (HRPC), curing the patient becomes difficult. Docetaxel has been shown to prolong survival in patients with HRPC by about 2 months in Phase III trials (4, 5) . In the trial, 56% of patients showed toxicities of Grade 3 or higher in the docetaxel group (4) .
The clinical efficacy of low doses of dexamethasone in the treatment of patients with HRPC has been reported previously (6 -11) . Although subjective and objective response rates varied, definite effects in these patients have been documented in terms of decreased prostate-specific antigen (PSA) levels or palliative activity (6 -11) . The exact mechanisms underlying decreases in PSA levels by dexamethasone are unclear, although dexamethasone has been proposed to suppress adrenal androgen (12) . In addition, anti-inflammatory effects may play a key role in the palliation of pain from bone metastases, and the in vitro and in vivo activity of dexamethasone against androgen-independent prostate cancer cell lines has been described (13 -15) . Low doses of dexamethasone have significant activity in HRPC with low toxicity and its potential for use in combination with novel agents has been reported (11) .
UFT is a combination of tegafur and uracil. UFT, as a single agent, has been reported to be effective in treating patients with HRPC (16, 17) . Oral cyclophosphamide has also been validated against HRPC when used alone (18, 19) and in combination with dexamethasone (20, 21) . In our previous study that examined oral combination therapy with cyclophosphamide, UFT and estramustine in patients with HRPC, 12 (57%) of 21 showed a 50% decline in PSA with minor toxicity (22) . In the present study, we evaluated an oral combination composed of dexamethasone, UFT and cyclophosphamide as a treatment for patients with HRPC. The regimen was designed with the goal of easy administration in an outpatient setting and with the expectation of minimal toxicity for most patients with HRPC in view of their advanced age and poor physical condition.
PATIENTS AND METHODS

PATIENTS
Fifty-seven patients with HRPC were treated with an oral combination of dexamethasone, UFT and cyclophosphamide at Osaka University Hospital from November 1996 to August 2008. Eligibility criteria included the following: HRPC, defined as serially increasing PSA values on three or more occasions at least 2 weeks apart or radiologically detected new or extensive lesions; a castration level of serum testosterone while receiving hormonal therapy; an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; and a life expectancy of 3 months.
Pre-treatment characteristics of all patients are shown in Table 1 . Patient age ranged from 49 to 90 years (median, 71 years). A bone scan, computed tomography (CT) or magnetic resonance imaging (MRI) was performed to evaluate the sites of metastatic diseases. Forty-seven patients had bone disease, eight had lymph node involvement and one had liver metastasis. In contrast, eight patients had only biochemical disease progression as evaluated by PSA. With respect to symptom status, 16 patients had bone pain due to metastasis.
Prior therapies are shown in Table 2 . As a primary hormonal therapy, all patients received complete androgen blockade of medical or surgical castration plus an antiandrogen. The antiandrogen was discontinued at least 4 weeks before initiating this regimen or prior chemotherapy to observe the antiandrogen withdrawal response. Seventeen patients (30%) had demonstrated a decline in serum PSA after antiandrogen withdrawal (antiandrogen withdrawal syndrome). Chemotherapies were administered in 36 patients (63%) after disease progression subsequent to initial hormonal therapy. Estramustine-based chemotherapies were administered in 26 patients (46%), low doses of oral dexamethasone were administered in 25 patients (44%) and docetaxel was administered in 2 patients.
TREATMENT
The treatment regimen, which was applied on an outpatient basis, consisted of dexamethasone (1.0 mg/day), UFT (400 mg/day as a dose of tegafur) and cyclophosphamide (100 mg/day), all given orally in two daily fractions. Four patients, all of whom were 80 years of age or more, received dexamethasone (0.5 mg/day), UFT (200 mg/day) and cyclophosphamide (50 mg/day). Patients were treated continuously 
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Chemotherapy with dexamethasone for HRPC until disease progression or unacceptable toxicity. The treatment was reintroduced after complete recovery from toxicity. All patients receiving an LHRH analogue continued the therapy.
ASSESSABILITY, TOXICITY AND RESPONSE CRITERIA
Patients underwent a physical examination and laboratory studies including complete blood cell counts, blood chemistry and PSA levels at a minimum of every 4 weeks. The primary endpoint was the proportion of patients with a decline of 50% in their PSA level. PSA progression was defined by the Prostate Cancer Clinical Trials Working Group 2 criteria (23). In brief, PSA response duration was assessed from the start of therapy to the date of PSA progression, which was defined as a 'PSA increase 25% and 2 ng/ml above the nadir, and which was confirmed by a second value 3 or more weeks later' for patients with PSA decline from baseline or 'PSA progression 25% and 2 ng/ ml' for patients with no PSA decline from baseline. A 'waterfall plot' was provided for the maximum decline in PSA that occurs at any point after treatment with dexamethasone, UFT and cyclophosphamide for each patient. Increases in PSA levels of .100% were capped at 100%. Patients with measurable disease as assessed by CT scan and/or MRI were evaluated according to the Response Evaluation Criteria in Solid Tumours criteria if the radiographic images were available. Symptomatic status corresponding to the date of the best PSA response was employed to evaluate symptomatic responses with respect to bone pain. Because we did not employ a formal pain scale assessment, the bone pain response was evaluated by analgesic dose and categorized as improved (defined as a decreased dose), stable (defined as the same dose) or progression (defined as an increased dose) when compared with analgesic administered at the start of therapy.
Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0, and were assessed every 4 weeks based on medical history, physical examination and laboratory studies. Dose reduction or discontinuation of this therapy was employed if a serious adverse effect developed.
The time to PSA progression and survival were calculated using the Kaplan -Meier method and comparisons were made using the log-rank test. Associations between pre-or post-treatment parameters and post-treatment PSA declines were evaluated using a Mann -Whitney U-test. A P value of ,0.05 was considered statistically significant. All statistical analyses were performed using SPSS software.
RESULTS
CLINICAL RESPONSE
Thirty-six (63%) of 57 patients showed a PSA decline of 50%. Figure 1 shows the maximum percent decrease in PSA levels with the combination therapy of dexamethasone, UFT and cyclophosphamide. The median follow-up from the start of this therapy was 19.6 months (range, 2.4 -84.4 months). Of 57 patients, 48 (84%) patients showed disease progression (PSA progression or objective progression), whereas 9 patients (16%) were on follow-up with a continued response (median, 19.6 months; range, 2.4 -42.7 months). The median time to PSA progression for the entire cohort was 7.2 months (95% confidence interval, 4.1 -10.1) as shown in Fig. 2 . In patients with a PSA decline of 50%, the median time to progression was 13.3 months (95% confidence interval, 8.9 -20.1). To determine any predictors of a better time to PSA progression, pre-treatment factors at baseline (age, pre-treatment PSA, duration of response to initial hormonal treatment, ECOG performance status, Gleason's score of the primary tumor and bone pain) were examined, as shown in Table 3 . The duration of response to initial hormonal treatment was associated with the time to PSA progression (P ¼ 0.045). Pre-treatment PSA, ECOG performance status and Gleason's score of the primary tumor were not statistically significant predictors. Among 26 patients with prior use of estramustine-based chemotherapies, 14 (54%) showed a PSA decline of 50%. One of two patients with prior use of docetaxel showed a PSA decline of 50%. Among 25 patients with prior use of low doses of oral dexamethasone, 10 (40%) showed a PSA decline of 50% with a median time to progression of 11.1 months (95% confidence interval, 2.3-28.2).
After failure of this therapy, 30 (63%) of 48 patients received docetaxel-based chemotherapy. Eighteen of the 28 evaluable patients (64%) showed a 50% decrease in PSA levels with docetaxel-based chemotherapy. Two patients were not evaluable due to insufficient PSA data. The median survival after initiation of docetaxel-based chemotherapy was 17 months (95% confidence interval, 7.9 -24.1). The median treatment duration of docetaxelbased chemotherapy was 9 months (range, 0.7 -51.8 months) and 14 (47%) of 30 patients showed adverse events of Grade 3 or 4, including 7 (23%) patients of neutropenia, 5 (17%) patients of anemia, 4 (13%) patients of infection, 1 (3%) patient of anorexia, 1 (3%) patient of fatigue and 1 (3%) patient of nail change.
Objective responses for measurable lymph node metastasis were assessable in seven patients. Among three patients with a PSA decline of 50%, two patients showed partial responses and one showed stable disease. Among four patients with a PSA decline of ,50%, four showed stable disease. Table 4 gives an assessment of bone pain based on PSA decline. Among 16 patients with symptomatic bone metastases, 11 (69%) had improvement and in 5 patients (31%), the pain became stable. Nine of 10 patients with a PSA decline of 50% showed improvement in bone pain, whereas only 2 of 6 patients with a PSA decline of ,50% showed improvement. Symptomatic responses of bone metastases were correlated with declines in serum PSA levels of 50% (P ¼ 0.017).
TOXICITY
The median duration of continuous full-dose treatment was 18 weeks (range, 1 -183 weeks). In 21 (37%) of 57 patients, dose reduction or discontinuation of UFT and/or cyclophosphamide was employed 1-60 weeks (median, 9 weeks) after initiating therapy due to moderate toxicities. The full-dose therapy was then resumed in three patients after recovery. Dexamethasone was continued in all patients until 
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Chemotherapy with dexamethasone for HRPC disease progression or treatment failure. Adverse events are shown in Table 5 . Most adverse events were mild and manageable on an outpatient basis. Only three (5%) patients showed neutropenia of Grade 3 or higher after 6 -20 weeks (median, 7 weeks) of initiating therapy.
DISCUSSION
In the current study, we retrospectively examined the efficacy of an oral combination of dexamethasone, UFT and cyclophosphamide in the treatment of patients with HRPC. Corticosteroids have long been recognized as active agents in the treatment of HRPC. Several types of glucocorticoids have been used in different doses for clinical trials examining HRPC. A study suggested that dexamethasone shows significantly greater activity in HRPC, in terms of PSA responses, compared with other corticosteroids such as prednisolone or hydrocortisone (11) . In our previous report that examined low doses of oral dexamethasone (0.5 -2 mg/day) in patients with HRPC, 23 (62%) of 37 patients showed a PSA decline of 50% (7). In several other trials of low doses of oral dexamethasone, 28 -61% of those with HRPC patients showed a PSA decline of 50% with mild adverse events (6,8 -11) . The palliation of pain from bone metastases was also reported. To summarize the trials examining low doses of oral dexamethasone in patients with HRPC, symptomatic responses of bone metastases were observed in 43 -63% of patients (6 -10) and correlated with declines in the serum PSA level of 50% (7,9,10).
Dexamethasone is often used as a premedication prior to docetaxel-based chemotherapy (4, 5) . The extent to which dexamethasone might contribute to the efficacy of chemotherapy has been speculated. In a previous report, high doses of dexamethasone (20 mg three times daily given for 1 day every 3 weeks) did not significantly contribute to the PSA response rate of docetaxel-based chemotherapy in HRPC (24) . A dose-dependent down-regulation in glucocorticoid receptor levels is one possible explanation (13) . Furthermore, high doses of dexamethasone possibly produce adverse effects such as Cushing's syndrome. Thus, low doses of dexamethasone are considered desirable for achieving sufficient response duration and minimizing side effects.
The administration of exogenous corticosteroids is known to suppress production of adrenal androgens and this inhibition of adrenal androgen production is assumed to account for the activity seen in the treatment of men with HRPC (12) . Furthermore, the in vitro and in vivo activity of dexamethasone against androgen-independent prostate cancer cell lines has been reported. In our previous study, dexamethasone inhibited the growth of androgen-independent prostate cancer cell lines, possibly through the disruption of the nuclear factor-kB dependent interleukin-6 pathway (13). Dexamethasone has also been reported to suppress tumorassociated angiogenesis and lymphangiogenesis by decreasing vascular endothelial growth factor (VEGF), interleukin-8 and VEGF-C expression through glucocorticoid receptors in androgen-independent prostate cancer cells (14, 15) . Further research is necessary to clarify the mechanisms underlying dexamethasone activity and to devise rational drug combinations. The toxicity profile of low doses of dexamethasone makes it an attractive candidate for combined therapy.
A review of earlier prospective randomized clinical trials shows that conventional intravenous administration of 5-fluorouracil (5-FU) and cyclophosphamide, both alone or in combination, produces ,15% objective responses (complete response or partial response) and has considerable toxicity (25, 26) . UFT is a mixture of tegafur and uracil in a 1:4 ratio and has the important advantage of improved oral bioavailability in comparison to 5-FU. Tegafur is hydroxylated and converted to 5-FU in vivo by hepatic microsomal enzymes (17) . Uracil inhibits the activity of hepatic dihydropyrimidine dehydrogenase, an enzyme involved in 5-FU catabolism, thereby leading to increased 5-FU levels when tegafur is administered with uracil (17) . In several trials of UFT, as a single agent or combined with leucovorin, 15 -19% of patients with HRPC showed a PSA decline of 50% with low toxicity (16, 17) . Oral cyclophosphamide has been shown to have greater activity against HRPC with less toxicity than intravenous cyclophosphamide. In trials of oral cyclophosphamide, as a single agent or combined with dexamethasone or other agents, 15 -68% of patients with HRPC showed a PSA decline of 50% (18 -22,27 -30) and symptomatic responses have also been reported (21, 28, 29) . Pre-clinical studies employing low doses of cyclophosphamide have demonstrated surprisingly potent and durable AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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antitumor effects in many tumor models of human prostate cancer (31, 32) . We preferred cyclophosphamide plus UFT because based on our previous experience, both are oral agents with less hematotoxicity (22) . Thus, the oral combination of dexamethasone, UFT and cyclophosphamide was selected and expected to have synergistic antitumor activity. Since these drugs cause antitumor effects through different mechanisms, a chemoresistant phenotype is unlikely to be induced by the selection pressure exerted by chemotherapeutic agents. Indeed, our study demonstrates that among the 25 patients previously treated with low doses of oral dexamethasone, 10 (40%) showed a PSA decline of 50%, which lasted a median of 11.1 months. Further study is required to determine whether this combination therapy is more active than low doses of dexamethasone alone.
In our study, only the duration of response to initial hormonal treatment was associated with the time to PSA progression. Pre-treatment PSA, ECOG performance status and Gleason's score of the primary tumor were not statistically significant predictors possibly because of small sample size.
Docetaxel-based chemotherapy has been reported to induce significant improvement in median survival by about 2 months in Phase III trials, but side effects occurred more often in the docetaxel group (4, 5) . In the present trial in which an oral combination of dexamethasone, UFT and cyclophosphamide was used, most adverse events were mild and neutropenia of Grade 3 or higher was shown in only three (5%) patients. This therapy could be easily performed on an outpatient basis for those with HRPC.
After failure of this therapy, 30 patients received docetaxel-based chemotherapy and 18 patients showed a PSA decline of 50%. The median survival after initiation of docetaxel-based chemotherapy was 17 months. The median treatment duration of docetaxel-based chemotherapy was 9 months and 14 (47%) of 30 patients showed adverse events of Grade 3 or 4. In trials of docetaxel-based chemotherapy, about 50% of patients with HRPC have been reported to show a PSA decline of 50% (4,5) and the median overall survival have been reported 17.5 months (4). Adverse events of Grade 3 or higher have been shown in 56% of patients in the docetaxel group (4). With respect to response rate, survivals and adverse events, this therapy might not deteriorate efficacy or tolerability of subsequent docetaxel-based chemotherapy. Recently, oral combinations of dexamethasone and cyclophosphamide have been reported to have activity in patients with HRPC, even after the failure of docetaxel-based chemotherapy (21, 29) . In this trial, only two patients received this therapy after failure of docetaxelbased chemotherapy and one patient showed a PSA decline of 50%. Further study is required to determine the timing of starting this regimen.
The present study has some limitations. Survival benefits could not be assessed because no control group was available in this trial. In addition, the possibility exists that the impact of this therapy on PSA endpoints will not translate into a worthwhile therapeutic effect on clinically meaningful endpoints (33) . To evaluate survival benefits, further randomized trials with well-organized protocols would be needed.
In conclusion, 36 (63%) of 57 patients with HRPC showed a PSA decline of 50% after treatment with an oral combination of dexamethasone, UFT and cyclophosphamide and the median time to progression was 7.2 months. Symptomatic responses of bone metastases were also proposed and correlated with declines in serum PSA levels of 50%. This treatment is a completely oral regimen and most adverse events were mild. This regimen may be a useful treatment option before or after docetaxel-based chemotherapy against HRPC.
